Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043209 · ClinicalTrials.gov registry record
Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 25
- Enrollment target
NCT03043209: Completed study, sponsored by The Cleveland Clinic.
NCT03043209 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03043209 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Investigators aim to use comparative exome and/or genome sequencing to discover causative molecular lesions for phenotypes hypothesized to be caused by somatic mutations. For this study, investigators have targeted hypertrophic cardiomyopathy.
Primary Outcome
The investigators will use DNA testing technology called "genomic sequencing"
Interventions
- GENETIC Genomic sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-08-30 |
| Est. Completion | 2022-12-28 |
What the finished NCT03043209 record still lists
NCT03043209 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Genomic sequencing is the first listed.
NCT03043209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03043209 about?
NCT03043209 is a clinical study titled "Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy". Investigators aim to use comparative exome and/or genome sequencing to discover causative molecular lesions for phenotypes hypothesized to be caused by somatic mutations. For this study, investigators have targeted hypertrophic cardiomyopathy.
What is the current status of trial NCT03043209?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2018-08-30. Estimated completion is 2022-12-28.
What interventions are being tested in trial NCT03043209?
The interventions under investigation include: Genomic sequencing (GENETIC).
Who is sponsoring clinical trial NCT03043209?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI